Lignan 7-hydroxymatairesinol in the context of post-genomic pharmacology
https://doi.org/10.17749/2070-4909/farmakoekonomika.2024.240
Abstract
Objective: to determine the molecular mechanisms of action of 7-hydroxymatairesinol (7(OH)MR), the main lignan of spruce extracts, characterized by oncoprotective and anti-inflammatory properties.
Material and methods. The analysis of 7(OH)MR was carried out by chemoinformatic approach using the combinatorial theory of solvability and the topological theory of recognition. The postgenomic approach makes it possible to assess the effect of drugs on genome transcription (transcriptome) and on the proteome as a whole.
Results. 7(OH)MP has anti-inflammatory (inhibition of 5-lipoxygenase, matrix metalloproteinase 2, mitogen-activated kinase p38-alpha, leukotriene В4 receptor, prostacyclin receptor), and oncoprotective (antioxidant effect due to inhibition of heme oxygenase-2, inhibition of cyclin-dependent kinases 3 and 4, epidermal growth factor, mTOR protein) pharmacological effects.
Conclusion. By reducing the expression of proliferative genes and genes involved in chronic inflammation, the 7(OH)MP molecule inhibits the proliferation of tumor cells. Pharmacoinformatic modeling showed that the anti-inflammatory effects of 7(OH)MR may contribute to increased lifespan in animal models.
Keywords
Supporting agencies: Thе work was supported by the grant of the Russian Science Foundation (Project No. 23-21-00154).
About the Authors
А. N. Rubashkina
Ivanovo State Medical Academy
Russian Federation
Russian Federation
Anna N. Rubashkina – Postgraduate, Chair of Oncology, Obstetrics and Gynecology
8 Sheremetyevsky Ave., Ivanovo 153012
I. Yu. Torshin
Federal Research Center “Computer Science and Control”, Russian Academy of Sciences
Russian Federation
Russian Federation
Ivan Yu. Torshin – PhD (Phys. Math.), PhD (Chem.), Senior Researcher
WoS ResearcherID: C-7683-2018
Scopus Author ID: 7003300274
44 corp. 2 Vavilov Str., Moscow 119333
O. A. Gromova
Federal Research Center “Computer Science and Control”, Russian Academy of Sciences
Russian Federation
Russian Federation
Olga A. Gromova – Dr. Med. Sc., Professor, Leading Researcher
WoS ResearcherID: J-4946-2017
Scopus Author ID: 7003589812
44 corp. 2 Vavilov Str., Moscow 119333
A. N. Galustyan
Saint Petersburg State Pediatric Medical University
Russian Federation
Russian Federation
Anna N. Galustyan – MD, PhD, Associate Professor, Chief of Chair of Pharmacology with a Course in Clinical Pharmacology and Pharmacoeconomics
2 Litovskaya Str., Saint Petersburg 194100
References
1. Gerstenmeyer E., Reimer S., Berghofer E., et al. Effect of thermal heating on some lignans in flax seeds, sesame seeds and rye. Food Chem. 2013; 138 (2-3): 1847–55. https://doi.org/10.1016/j.foodchem.2012.11.117.
2. Gromova O.A., Torshin I.Yu., Rubashkina A.N., et al. Systematic analysis of fundamental and clinical studies of lignan 7-hydroxymatairesinol. Effective Pharmacotherapy. 2019; 15 (13): 34–41 (in Russ.).
3. Udani J.K., Brown D.J., Tan M.O., Hardy M. Pharmacokinetics and bioavailability of plant lignan 7-hydroxymatairesinol and effects on serum enterolactone and clinical symptoms in postmenopausal women: a single-blinded, parallel, dose-comparison study. J Am Coll Nutr. 2013; 32 (6): 428–35. https://doi.org/10.1080/07315724.2013.849578.
4. Lina B., Korte H., Nyman L., Unkila M. A thirteen week dietary toxicity study with 7-hydroxymatairesinol potassium acetate (HMRlignan) in rats. Regul Toxicol Pharmacol. 2005; 41 (1): 28–38. https://doi.org/10.1016/j.yrtph.2004.09.001.
5. Wolterbeek A.P., Roberts A., Korte H., et al. Prenatal developmental toxicity study with 7-hydroxymatairesinol potassium acetate (HMRlignan) in rats. Regul Toxicol Pharmacol. 2004; 40 (1): 1–8. https://doi.org/10.1016/j.yrtph.2004.04.001.
6. Saarinen N.M., Wärri A., Mäkelä S.I., et al. Hydroxymatairesinol, a novel enterolactone precursor with antitumor properties from coniferous tree (Picea abies). Nutr Cancer. 2000; 36 (2): 207–16. https://doi.org/10.1207/S15327914NC3602_10.
7. Zhuravlev Yu.I., Rudakov K.V., Torshin I.Yu. Algebraic criteria of local solvability and regularity as a tool for studying the morphology of amino acid sequences. Proceedings of Moscow Institute of Physics and Technology. 2011; 3 (4): 45–54 (in Russ.).
8. Torshin I.Yu., Rudakov K.V. On the application of the combinatorial theory of solvability to the analysis of chemographs. Part 1: Fundamentals of modern chemical bonding theory and the concept of the chemograph. Pattern Recognit Image Anal. 2014; 24 (1): 11–23. https://doi.org/10.1134/S1054661814010209.
9. Torshin I.Yu. On solvability, regularity, and locality of the problem of genome annotation. Pattern Recognit Image Anal. 2010; 20 (3): 386–95. https://doi.org/10.1134/S1054661810030156.
10. Torshin I.Yu., Gromova O.A. Expert data analysis in molecular pharmacology. Moscow: Moscow Center for Continuous Mathematical Education; 2012: 687 pp. (in Russ.).
11. Torshin I.Yu., Rubashkina A.N., Lapochkina N.P., Gromova O.A. Chemoreactome analysis of 7-hydroxymatairesinol, 17-estradiol, phytoestrogen, β-sitosterol and epigallocatechin-3-gallate. Obstetrics, Gynecology and Reproduction. 2020; 14 (3): 347–60 (in Russ.). https://doi.org/10.17749/2313-7347/ob.gyn.rep.2020.152.
12. Torshin I.Yu., Gromova O.A., Frolova D.E., et al. Dose-dependent chemotranscriptomics analysis of the differential effects of vitamin D3 on gene expression in human neuronal progenitor cells NPC and in MCF7 tumor cells. Farmakokinetika i farmakodinamika. 2018; 2: 35–51 (in Russ.). https://doi.org/110.24411/2587-7836-2018-10013.
13. Torshin I.Yu. Sensing the change: from molecular genetics to personalized medicine. 1st ed. Nova Science Publishers; 2009: 366 pp.
14. Torshin I.Yu., Rubashkina A.N., Gromova O.A. Chemotranscriptomic analysis of 7-hydroxymatairesinol-related effects on MCF7 human breast tumor cells. Obstetrics, Gynecology and Reproduction. 2023; 17 (5): 584–96 (in Russ.). https://doi.org/10.17749/2313-7347/ob.gyn.rep.2023.409.
15. Gromova O.A., Frolova D.E., Torshin I.Yu., Filimonova M.V., Sorokina M.A., Reyer I.A., Limanova O.A., Fedotova L.E., Maiorova L.A. Antitumor effects of vitamin B12 in vitro, in vivo, in silico. FARMAKOEKONOMIKA. Sovremennaya farmakoekonomika i farmakoepidemiologiya / FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology. 2024: [accepted manuscript] (in Russ.). https://doi.org/10.17749/2070-4909/farmakoekonomika.2024.231.
16. Torshin I.Yu., Rudakov K.V. On metric spaces arising during formalization of problems of recognition and classification. Part 2: Density properties. Pattern Recognit Image Anal. 2016; 26 (3): 483–96. https://doi.org/10.1134/S1054661816030202.
17. Torshin I.Yu., Rudakov K.V. Combinatorial analysis of the solvability properties of the problems of recognition and completeness of algorithmic models. Part 2: Metric approach within the framework of the theory of classification of feature values. Pattern Recognit Image Anal. 2017; 27 (2): 184–99. https://doi.org/10.1134/S1054661817020110.
18. Cosentino M., Marino F., Maio R.C., et al. Immunomodulatory activity of the lignan 7-hydroxymatairesinol potassium acetate (HMR/lignan) extracted from the heartwood of Norway spruce (Picea abies). Int Immunopharmacol. 2010; 10 (3): 339–43. https://doi.org/10.1016/j.intimp.2009.12.005.
19. Spilioti E., Holmbom B., Papavassiliou A.G., Moutsatsou P. Lignans 7-hydroxymatairesinol and 7-hydroxymatairesinol 2 exhibit anti-inflammatory activity in human aortic endothelial cells. Mol Nutr Food Res. 2014; 58 (4): 749–59. https://doi.org/10.1002/mnfr.201300318.
20. Yang D., Xiao C.X., Su Z.H., et al. (-)-7(S)-hydroxymatairesinol protects against tumor necrosis factor-alpha-mediated inflammation response in endothelial cells by blocking the MAPK/NF- κB and activating Nrf2/HO-1. Phytomedicine. 2017; 32: 15–23. https://doi.org/10.1016/j.phymed.2017.04.005.
21. Samson K. LEE011 CDK inhibitor showing early promise in drug-resistant cancers. Oncol Times. 2014; 36 (3): 39–40. https://doi.org/10.1097/01.COT.0000444043.33304.c1.
22. Liang W., Wu X., Fang W., et al. Network meta-analysis of erlotinib, gefitinib, afatinib and icotinib in patients with advanced non-small-cell lung cancer harboring EGFR mutations. PLoS One. 2014; 9 (2): e85245. https://doi.org/10.1371/journal.pone.0085245.
23. Lamming D.W., Ye L., Sabatini D.M, Baur J.A. Rapalogs and mTOR inhibitors as anti-aging therapeutics. J Clin Invest. 2013; 123 (3): 980–9. https://doi.org/10.1172/JCI64099.
24. Rogowski M., Gollahon L., Chellini G., Assadi-Porter F.M. Uptake of 3-iodothyronamine hormone analogs inhibits the growth and viability of cancer cells. FEBS Open Bio. 2017; 7 (4): 587–601. https://doi.org/10.1002/2211-5463.12205.
25. Aouad P., Saikali M., Abdel-Samad R., et al. Antitumor activities of the synthetic retinoid ST1926 in two-dimensional and three-dimensional human breast cancer models. Anticancer Drugs. 2017; 28 (7): 757–70. https://doi.org/10.1097/CAD.0000000000000511.
26. Saarinen N.M., Huovinen R., Wärri A., et al. Uptake and metabolism of hydroxymatairesinol in relation to its anticarcinogenicity in DMBA-induced rat mammary carcinoma model. Nutr Cancer. 2001; 41 (1-2): 82–90. https://doi.org/10.1080/01635581.2001.9680616.
27. Miura D., Saarinen N.M., Miura Y., et al. Hydroxymatairesinol and its mammalian metabolite enterolactone reduce the growth and metastasis of subcutaneous AH109A hepatomas in rats. Nutr Cancer. 2007; 58 (1): 49–59. https://doi.org/10.1080/01635580701308133.
28. Bylund A., Saarinen N., Zhang J.X., et al. Anticancer effects of a plant lignan 7-hydroxymatairesinol on a prostate cancer model in vivo. Exp Biol Med. 2005; 230 (3): 217–23. https://doi.org/10.1177/153537020523000308.
29. Katsuda S., Yoshida M., Saarinen N., et al. Chemopreventive effects of hydroxymatairesinol on uterine carcinogenesis in Donryu rats. Exp Biol Med. 2004; 229 (5): 417–24. https://doi.org/10.1177/153537020422900510.
30. Oikarinen S.I., Pajari A., Mutanen M. Chemopreventive activity of crude hydroxsymatairesinol (HMR) extract in Apc(Min) mice. Cancer Lett. 2000; 161 (2): 253–8. https://doi.org/10.1016/s0304-3835(00)00662-5.
31. Gromova O.A., Rubashkina A.N., Filimonova M.V., et al. Adjuvant therapy of the lignane 7-hydroxymatairesinol as the method to increase the oncologic safety of estrogen taking. Effective Pharmacotherapy. 2018; 14 (13): 14–9 (in Russ.).
32. Rubashkina A.N., Lapochkina N.P., Torshin I.Yu., Gromova O.A. The role of 7-hydroxymatoiresinol in the modulation of estrogen metabolism and therapy for mastopathy. Gynecology. 2020; 22 (4): 43–8.
What is already known about thе subject?
- 7-hydroxymatairesinol (7(ОН)МР) is the main lignan of spruce extracts, which has oncoprotective and anti-inflammatory properties
- An important feature of 7(OH)MR is its high safety of use
- 7(ОН)МР does not exert teratogenic or allergic effects
What are the new findings?
- It was shown that the anti-inflammatory mechanism of the molecular action of 7(OH)MR includes the inhibition of 5-lipoxygenase, matrix metalloproteinase 2, mitogen-activated kinase p38-alpha, leukotriene B4 receptor, prostaglandin receptor
- The oncoprotective mechanism of 7(OH)MR molecular action is based on the inhibition of heme oxygenase-2, cyclin-dependent kinases 3 and 4, epidermal growth factor, and mTOR protein
- According to the experimental study, 7(OH)MR in doses of 60 and 120
mg/day inhibits the growth of Ehrlich solid carcinoma even when provoked with estradiol
How might it impact the clinical practice in the foreseeable future?
- The oncoprotective and anti-inflammatory properties of 7(ОН)МР indicate the prospects for its use in clinical practice of oncologists and gyne-
cologists
Review
For citations:
Rubashkina А.N., Torshin I.Yu., Gromova O.A., Galustyan A.N. Lignan 7-hydroxymatairesinol in the context of post-genomic pharmacology. FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology. 2024;17(2):191-199. (In Russ.) https://doi.org/10.17749/2070-4909/farmakoekonomika.2024.240
Views:
518
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Email this article 